New Biopharma Company Acelyrin Is on the Hunt for Immunotherapy Drugs

Breanna De Vera

Breanna de Vera is dot.LA's editorial intern. She is currently a senior at the University of Southern California, studying journalism and English literature. She previously reported for the campus publications The Daily Trojan and Annenberg Media.

New Biopharma Company Acelyrin Is on the Hunt for Immunotherapy Drugs
Photo by Jaron Nix on Unsplash

A new biopharmaceutical startup, ACELYRIN, that launched this week is on the hunt for new immunological therapies that it can bring to market.

The company just closed a round backed by Westlake Village BioPartners, a two-year-old venture capital fund that recently raised $500 million.

Flush with an undisclosed amount of cash, ACELYRIN is looking to fund research done in academia or by smaller companies that will lead to the commercialization of new drugs.

"At the end of the day, what we really want to do together is we want to build a long-term, sustainable biopharma company, with initial focus on immunology, that ultimately has a pipeline with the potential to be really meaningful to patients with serious diseases," said co-founder and chief executive Shao-Lee Lin. "Our ultimate goal is to have a fully integrated biopharma company with broad research, development and commercialization capabilities."

Lin created the company with Bob Carey, whom she met at Horizon Therapeutics, a biopharmaceutical company based in Lake Forest, Illinois, that focuses on rare diseases, rheumatology and primary care.

Carey was Horizon's chief business officer when Lin joined as its first chief scientific officer as well as the head of research and development. They worked on developing drugs like Tepezza, a thyroid eye disease medicine and Krystexxa, a gout medication. Carey will serve as ACELYRIN's chief operating officer.

Bob Carey is co-founder and. chief operating officer at ACELYRIN.

Shao-Lee Lin

Shao-Lee Lin is co-founder and chief executive at ACELYRIN.

"[Carey] contributed tremendously to the transformation of [Horizon] from sort of a specialty pharma company to a rare-disease-focused, and then ultimately to a development-stage organization, which is when I joined — when it started to think about having an R&D organization," said Lin.

They want to take ACELYRIN in a similar direction, to become a company that has arms in research and development, as well as one that commercializes its medicines. They plan to partner with big pharmaceutical companies to take on projects that may have been sidelined.

It's a common model among smaller and newer companies, according to Karen Van Nuys, a professor at the USC Price Price School of Public Policy and in the Schaeffer Center for Health Policy and Economics.

"[These companies] often focus on initial discovery and early development phases, but then partner with a larger, more established pharmaceutical company when the time comes to conduct large-scale trials and go through the formal drug approval process," said Van Nuys.

ACELYRIN hopes to eventually be able to keep all steps of projects within their company. For now, they are searching for partners in big pharma and academia while they grow.

If successful, Lin and Carey think they will build on Los Angeles' status as California's third biotech hub, after San Diego and San Francisco. Last year, L.A. County received over $1.1 billion from the government for life science research and development, according to a recent report by Biocom.

Subscribe to our newsletter to catch every headline.


Ex-Disney Execs’ Candle Media Buys Social Media Company ATTN: for $100M

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

Ex-Disney Execs’ Candle Media Buys Social Media Company ATTN: for $100M
Photo provided by ATTN:

Candle Media, the firm run by ex-Disney execs Kevin Mayer and Tom Staggs, has bought social media creative company ATTN: for $100 million.

Los Angeles-based ATTN: (pronounced “attention”) produces content geared toward Gen Z and Millennial viewers. The company has created original series for Facebook, TikTok, and Twitch, as well as TV networks like ABC and NBC, and streaming services like Hulu and Apple TV. Launched in 2014, ATTN:’s brand studio and creative agency has also worked with Amazon, Ford and Google, among others.

Read more Show less

Marijuana and the Metaverse: How LA Cannabis Startups Are Lighting Up the Virtual Realm

Nick Kazden
Nick Kazden is a freelance writer who lives and writes in Los Angeles.
Marijuana and the Metaverse: How LA Cannabis Startups Are Lighting Up the Virtual Realm
Image courtesy of Crypto Cannabis Club

With West Hollywood becoming a hub for cannabis consumption lounges and many Silicon Beach companies embracing virtual reality, it was only a matter of time before two of Los Angeles’ two burgeoning industries started mingling.

Read more Show less

Old Guard on High Alert as Streaming and New Tech Storm Upfronts

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Old Guard on High Alert as Streaming and New Tech Storm Upfronts
Netflix and Google Are Poised to Dominate L.A. After the Pandemic

Are the upfronts turning into TV execs’ personal “Black Mirror'' episode?

The annual feeding frenzy—in which C-suite television executives auction off highly-viewed (and costly) advertising time slots— is changing as new streaming behemoths shake up the market. The event often gives viewers and industry watchers insight on what shows are poised to become cultural phenomena, but that too seems to be disrupted at this year’s proceedings.

It’s been two years since major networks and television players convened in New York for a week, and it’s clear that technology is going to change a lot about how the process works.

Read more Show less